UroToday

SUO 2025: ZIRCON-X: Impact of 89Zr-Girentuximab PET/CT Versus Conventional Imaging on Clinical Decision-Making in Patients with Indeterminate Renal Masses

(UroToday.com) The 2025 SUO annual meeting featured a kidney session and a presentation by Dr. Brian Shuch discussing ZIRCON-X and the impact of 89 Zr-girentuximab PET/CT versus conventional imaging ...
UroToday

2024 American Society of Clinical Oncology (ASCO)

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...
UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

LITESPARK-033 and the Development of Belzutifan plus Zanzalintinib in Kidney Cancer - Cristina Suárez

Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.
UroToday

Non-Muscle Invasive Bladder Cancer

AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
UroToday

Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC - Yudai Ishiyama

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
UroToday

ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426

(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
UroToday

AUA 2026: Transurethral Robotic en-bloc TURBT-Challenging Status Quo

(UroToday.com) The Friday afternoon plenary session opened with the prestigious John K. Lattimer Lecture, one of the AUA’s most prestigious lectureships honoring Dr. John K. Lattimer, a pioneering ...
UroToday

SNMMI 2025: Development of PSMA Targeting Radioligand 161Tb-LNC1011 for Prostate Cancer Theranostics

(UroToday.com) The 2025 SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for ...
UroToday

AUA 2026: Association of Serum Kidney Injury Molecule-1 (KIM-1) with Treatment Response and Survival in Metastatic Renal Cell Carcinoma

(UroToday.com) The 2026 American Urological Association (AUA) Annual Meeting featured a poster presentation by Dr. Akihiro Kumono and colleagues from Tokyo Women’s Medical University evaluating the ...
UroToday

PSMA and Beyond 2025: Beyond PSMA in Prostate Cancer: STEAP1, DLL3, and CD46

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...